YH1885L(Revaprazan) + Esomeprazole 20mg + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-erosive Reflux Disease
Conditions
Non-erosive Reflux Disease
Trial Timeline
Jan 1, 2013 → Apr 1, 2014
NCT ID
NCT01750437About YH1885L(Revaprazan) + Esomeprazole 20mg + placebo
YH1885L(Revaprazan) + Esomeprazole 20mg + placebo is a phase 2 stage product being developed by Yuhan for Non-erosive Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01750437. Target conditions include Non-erosive Reflux Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01750437 | Phase 2 | Completed |
Competing Products
6 competing products in Non-erosive Reflux Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85